Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breas

求助中 10 由 ! 发布于 2025/2/4 21:15:03

DOI:10.1200/jco.2024.42.17_suppl.lba1000
文献类型：期刊论文
补充材料：只需要正文
文献链接：https://doi.org/10.1200/jco.2024.42.17_suppl.lba1000

American Society of Clinical Oncology (ASCO)

Abstract：LBA1000 Background: T-DXd is approved for HER2-low (IHC 1+ or 2+/ISH-negative) mBC after ≥1 line of chemotherapy (CT). DB-06 (NCT04494425) evaluated T-DXd in pts with HER2-low or -ultralow (

应助信息

等您来应助

上传文件

11小时前

Book学术机器人

2025/2/4 21:15:03 未找到该文献，机器人已退出，请等待人工下载

2025/2/4 21:15:03 Book学术AI机器人收到请求，开始寻找文献

2025/2/4 21:15:03 已向机器人发送请求

11小时前

! 发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:WileyAn innovative walnut cracker: Self-grading and multi-station extrusion mechanism with high efficiency